Neurobiology of Disease

B-Lymphocyte-Mediated Delayed Cognitive Impairment following Stroke

Kristian P. Doyle,1,2 Lisa N. Quach,1,6 Montse Solé,1,3 Robert C. Axtell,1 Thuy-Vi V. Nguyen,1,2 Gilberto J. Soler-Llavina, Sandra Jurado,4 Jullet Han,1 Lawrence Steinman,1 Frank M. Longo,5 Julie A. Schneider,5 Robert C. Malenka,4 and Marion S. Buckwalter1,6

1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, 2Department of Immunobiology, Department of Neurology, and the Arizona Center on Aging, University of Arizona, Tucson, Arizona 85724, 3Neurosciences Institute and Department of Biochemistry and Molecular Biology, Medicine Faculty, Universitat Autonoma de Barcelona, Barcelona 08193, Spain, 4Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California 94305, 5Department of Pathology and Neurological Sciences, Rush Alzheimer’s Disease Center Rush University Medical Center, Chicago, Illinois 60612, and 6Department of Neurosurgery, Stanford University School of Medicine, Stanford, California 94305

Each year, 10 million people worldwide survive the neurologic injury associated with a stroke. Importantly, stroke survivors have more than twice the risk of subsequently developing dementia compared with people who have never had a stroke. The link between stroke and the later development of dementia is not understood. There are reports of oligoclonal bands in the CSF of stroke patients, suggesting that in some people a B-lymphocyte response to stroke may occur in the CNS. Therefore, we tested the hypothesis that a B-lymphocyte response to stroke could contribute to the onset of dementia. We discovered that, in mouse models, activated B-lymphocytes infiltrate infarcted tissue in the weeks after stroke. B-lymphocytes undergo isotype switching, and IgM, IgG, and IgA antibodies are found in the neuropil adjacent to the lesion. Concurrently, mice develop delayed deficits in LTP and cognition. Genetic deficiency, and the pharmacologic ablation of B-lymphocytes using an anti-CD20 antibody, prevents the appearance of delayed cognitive deficits. Furthermore, immunostaining of human postmortem tissue revealed that a B-lymphocyte response to stroke also occurs in the brain of some people with stroke and dementia. These data suggest that some stroke patients may develop a B-lymphocyte response to stroke that contributes to dementia, and is potentially treatable with FDA-approved drugs that target B cells.

Key words: B-lymphocyte; dementia; immunology; stroke

Introduction

The 7 million Americans currently living with the aftereffects of stroke are at increased risk of developing dementia, and approximately one-third will eventually suffer from vascular dementia. There is evidence of immunoglobulin synthesis in the CSF even in the first few weeks after stroke. However, in human stroke survivors, there is evidence of immunoglobulin synthesis in the CSF even in the weeks to months after stroke. In mice, immune responses are not well characterized beyond the first few weeks after stroke. In many of these patients, dementia might be caused by an associated comorbidity, but even after controlling for dementia risk factors, such as hypertension, hypercholesterolemia, diabetes, and age, the occurrence of a single stroke increases the risk of developing new dementia by at least twofold (Leys et al., 2005; Savva and Stephan, 2010). The mechanism(s) behind this increased dementia risk are unknown.

We focused here on the hypothesis that stroke can elicit a chronic, injurious B-lymphocyte-mediated response that impairs cognition. In mice, immune responses are not well characterized beyond the first few weeks after stroke. However, in human stroke survivors, there is evidence of immunoglobulin synthesis in the CSF even in the weeks to months after stroke (Roström and Link, 1981; Tsementzis et al., 1986; Prüss et al., 2012). B-lymphocytes themselves have not previously been reported in human or mouse strokes, but B-lymphocyte aggregates occur in the meninges in both experimental autoimmune encephalomyelitis (EAE) in mice and multiple sclerosis (MS) in humans (Galea et al., 2007), and also in the lesion in a mouse model of spinal cord injury (Ankeny and Popovich, 2010). In the injured spinal cord, they produce autoantibodies that bind to nuclear antigens that can cross-react with neuronal antigens, and mice that lack B-lymphocytes have improved recovery (Ankeny et al., 2006; Ankeny and Popovich, 2010). Ectopic lymphoid tissues that contain B- and T-lymphocytes are also observed outside the CNS in both pathogenic and nonpathogenic chronic inflammatory states and correlate with increased severity of...
autoimmune disease or infection (Carragher et al., 2008; Varallyay et al., 2013).

To investigate the possibility that a B-lymphocyte-mediated immune response after stroke might mediate some of the increased risk of dementia in stroke survivors, we first asked whether chronic inflammation occurs weeks after stroke in wild-type mice. We characterized the immune response that was present 7 weeks after stroke, with particular attention to B-lymphocytes and antibody-producing plasma cells. We next developed a mouse model of delayed cognitive decline after stroke using wild-type C57BL/6J mice and confirmed it in a second mouse strain, BALB/CJ mice. We then used B-cell-deficient mice and a B-cell-depleting antibody to test the hypothesis that B-lymphocyte responses cause delayed cognitive impairment. Finally, we obtained brain tissue from human subjects that suffered from stroke and dementia and asked whether there was a difference in B-lymphocyte density and IgG immunoreactivity in the brain compared with controls.

Our data indicate that mice develop a B-lymphocyte-mediated autoimmune response that causes delayed cognitive dysfunction and that some humans develop a similar response.

**Materials and Methods**

Mice. Adult mice were male, 3- to 5-months-old, C57BL/6, mullMT (C57BL/6) background, Jax stock #002288), or BALB/CJ purchased from the The Jackson Laboratory. All procedures met National Institutes of Health guidelines with the approval of the Stanford University Institutional Animal Care and Use Committee.

Stroke surgery. In BALB/CJ mice, distal middle cerebral artery occlusion (DMCAO) was performed as previously described (Doyle et al., 2012). Sham surgeries were identical to stroke surgeries, except for ligation of the distal middle cerebral artery. C57BL/6J mice were given 8% oxygen for 1 h immediately after DMCAO. We refer to this variation of DMCAO as DH stroke (DMCAO + hypoxia). This period of hypoxia induces vasoconstriction and compensates for extensive collateralization between the anterior cerebral artery and middle cerebral artery present in C57BL/6J mice (Doyle et al., 2012).

For all experiments, mice received one dose of the antibiotic cefazolin, 25 mg/kg s.c., immediately after surgery. Mice that underwent sham DH stroke were also given 8% oxygen for 1 h immediately after surgery. DMCAO in BALB/CJ mice and DH stroke in C57BL/6J mice generate equivalent lesions (Doyle et al., 2012). Core body temperature was maintained at 37°C throughout surgery. Mice were returned to their cages with free access to food and water after closure of the surgical wound. Infarct assessment was performed as previously described using 2,3,5-triphenyltetrazolium chloride staining (Doyle et al., 2012). Sixty minutes of transient proximal intraluminal filament middle cerebral artery occlusion (MCAO) was performed as previously described (Arac et al., 2011). For photothrombotic stroke, an incision was made on the top of the head to expose the skull. A 5-mm-diameter optic cable connected to a metal halide fiber-optic illuminator (Dolan-Jener MH-100) was then placed on top of the skull using a stereotactic frame. Mice were injected intraperitoneally with 40 mg/kg Rose Bengal (Sigma, #330000-5G) dissolved in saline, and 5 min later the light source was turned on for 15 min.

**Mouse immunohistochemistry and immunofluorescence.** Hematoxylin and eosin staining and immunostaining were performed as described using standard techniques on PFA-fixed 40 µm coronal brain sections (Doyle et al., 2010). Primary antibodies were against B220 (biotinylated, 1:500; BD Biosciences, 553085), CD11c (1:500; Abcam, ab33483), IgG (biotinylated, 1:1000; Vector, BA-2000), CD3 (1:500; BD Biosciences, 550277), MHCII (I-A/I-E, 1:500; BD Biosciences, 553621), CD68 (1:1000; Serotec, MCA1957), and Iba1 (1:1000; Wako, 190-119741). The specificity of primary antibody staining was confirmed using control sections treated with secondary antibody alone. For Table 1, cells were counted using National Institutes of Health ImageJ cell counting software in the stroke core in two sections per mouse (n = 6). For Figure 7C, quantification of CD3 immunostaining was performed on two sections per mouse blinded to treatment/genotype. Quantification of IgG immunostaining was performed in one section per mouse blinded to treatment. A photomicrograph of the region shown in Figure 8E (black box) was assayed for mean gray value using ImageJ.

**Brain flow cytometry.** Cells were stained with fluorescent antibodies (CD3, CD19, and CD138) using standard techniques, analyzed using a FACScan flow cytometer (BD Biosciences) and quantified using FlowJo software (TreeStar). To isolate immune cells in the brain 7 weeks following stroke, we pooled 10 mice and incubated brain homogenates with collagenase (Roche) and DNase (Sigma) for 1 h at 37°C and purified the cells by Percoll gradient centrifugation. Cells were gated by forward scatter and side scatter to identify lymphocytes, using spleen as a control. For Figure 1E, cells were subsequently gated by CD19 high expression.

**ELISA identification of antibody isotypes in the brain.** Seven weeks following stroke or sham surgery, mice were perfused with saline, and the cortex and hippocampus were dissected. Tissue was immersed in lysis buffer (Sigma CellLyte MT Mammalian Tissue Lysis Reagent containing Sigma protease inhibitor mixture and Sigma phosphatase inhibitor mixture 2) at a ratio of 1:20 and sonicated. Following centrifugation, the protein concentration of the supernatant was calculated and normalized to 10 mg/ml. Antibody concentrations in the cortex and hippocampus were then measured using a rapid ELISA mouse antibody isotyping kit (Thermo Scientific) according to the manufacturer’s instructions (sham n = 3, stroke n = 5–7).

**Multiplex immunoassay for quantifying cytokine and antibody concentrations in plasma and in the stroke lesion.** After stroke or sham surgery, 100–400 µl blood was collected by cardiac puncture under anesthesia, placed in EDTA tubes, and centrifuged to obtain plasma. Mice were then perfused with sterile saline, and dissected brain tissue immersed in lysis buffer (Sigma CellLyte MT Mammalian Tissue Lysis Reagent containing Sigma protease inhibitor mixture and Sigma phosphatase inhibitor mixture 2) at a ratio of 1:20 and sonicated. Following centrifugation, the protein concentration of the supernatant was calculated and normalized to 1 mg/ml. Cytokines, chemokines, and antibody isotypes were then detected and quantified by multiplex immunoassay. Mouse multiplex kits were purchased from Affymetrix and Millipore and used according to the manufacturer’s recommendations. Each sample was measured in duplicate. Plates were read using a Lumines instrument, and results were analyzed using Prism software.

**Acute slice preparation and whole-cell recordings.** Mice were decapitated after deep isoflurane anesthesia. The forebrain was removed and placed in ice-cold dissection media consisting of 228 mM sucrose, 26 mM NaHCO3, 1 mM glucose, 2.5 mM CaCl2, and 1 mM MgCl2, 8 mM NaCl, 5 mM EGTA, 1 mM MgCl2, and 1 mM CaCl2. The sodium phosphocreatine, 8 mM NaCl, 5 mM EGTA, 1 mM MgCl2, 4 mM Mg-ATP, 0.3 mM Na-GTP, and 1 mM QX-314. Electrode resistances

---

**Table 1. Immune cells within the stroke lesion**

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Cells per section (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-lymphocytes (B220+)</td>
<td>1286 ± 134</td>
</tr>
<tr>
<td>T-lymphocytes (CD3+)</td>
<td>1226 ± 128</td>
</tr>
<tr>
<td>CD68+</td>
<td>11,174 ± 1176</td>
</tr>
<tr>
<td>MHCII+</td>
<td>1487 ± 1214</td>
</tr>
<tr>
<td>CD11c+</td>
<td>1782 ± 1112</td>
</tr>
</tbody>
</table>

*Relative frequency of T- and B-lymphocytes, CD68+ macrophages, MHCII+ cells, and CD11c+ cells within the stroke lesion 7 weeks following DH stroke in C57BL/6J mice (n = 6).*
Animal experiments were performed in C57BL/6J mice. Scale bar, 250 μm. C, Fluorescent immunostaining for the B-lymphocyte marker B220 (red) and the dendritic cell marker CD11c (green) shows that B cells and T cells are compartmentalized 7 weeks following DH stroke. Scale bar, 25 μm. Images are representative of 10 mice that underwent stroke. D, Fluorescent immunostaining for the B-lymphocyte marker B220 (magenta) and the T cell marker CD3 (green) reveals that B cells and T cells are compartmentalized 7 weeks following DH stroke. Scale bar, 100 μm. E, Flow cytometry revealed that 9% of CD19 + B-lymphocytes present in the stroke lesion were CD19 + CD138 + plasma cells (n = 10 pooled stroke lesions). F, G, Representative images of IgG immunostaining in the hippocampus 7 weeks following stroke or sham surgery (n = 10). M, Determination of antibody isotypes present in the cortex and hippocampus 7 weeks following stroke or sham surgery (stroke n = 7; sham n = 3). *p < 0.05, compared with sham. Error bars indicate SD. H, I, Immunostaining for the B-cell marker B220 4 weeks after stroke in two additional stroke models performed in C57BL/6J mice: MCAO (I) and photothrombotic stroke (PT stroke) (J). Scale bars, 500 and 100 μm (lower and higher magnifications, respectively).

**Object location test (OLT).** Mice were habituated to an empty arena containing spatial cues on the walls for 5 min. Mice were then returned to their home cage while four objects were placed in the arena. The objects were children’s building blocks of different shapes and colors, and each was placed in a corner of the arena, 5 cm from the walls. Mice were allowed to explore the objects for 5 min and then were returned to their home cage. The positions of two of the objects were then switched. Mice were returned to the arena, and the number of rears on each object was recorded for a further 5 min. This test is based on the spontaneous tendency of rodents to spend more time exploring an object that has been relocated.

**Treatment with anti-CD20 antibody.** Mice were injected in the tail vein with 10 mg/kg anti-CD20 antibody (clone 5D2, isotype IgG2a, Genentech), or isotype control (anti-ragweed IgG2a, Genentech) beginning 5 d after stroke or sham surgery (n = 10 per group). Drug treatment was repeated every 2 weeks thereafter, and B-cell ablation was monitored every 7 d after drug treatment by flow cytometric analysis of a tail blood sample from each mouse using antibodies against CD3 (T-lymphocytes) and CD19 (B-lymphocytes).

**Human tissue.** Paraffin-embedded human brain sections from the stroke core of subjects with vascular dementia and stroke were obtained from the Rush Religious Orders Study (16 subjects) (Bennett et al., 2012a) and the Rush Memory and Aging Project (5 subjects) (Bennett et al., 2012b). Tissue was from 21 stroke patients of mixed gender. Hematoxylin and eosin sections superficial and deep to the lesion were studied to ensure that infarcted tissue was within the sections used for study. Frontal cortex sections from 9 age-matched controls that did not have either stroke or dementia were also provided. Tissue was immunostained using standard techniques with an anti-CD20 antibody (1:500 Dako M0755). Total CD20 + cells present in each slide were counted and divided by the area of tissue present on the slide to obtain the number of...
B-lymphocytes/cm². Immunostaining for IgG was performed with biotinylated anti-human IgG (1:1000; Vector, BA-3000).

Statistical analysis. All animal experiments were designed to ensure humane endpoints and minimize numbers of mice and suffering. Allocation of mice into stroke and sham groups was performed randomly, and behavior experiments were performed with the experimenter blind to treatment group. For immunostaining and electrophysiology, blinding was not possible because of the stroke lesion being clearly visible in the stroke groups. Data are expressed as mean ± SEM unless otherwise indicated in the figure legend. Statistical analyses were performed with Prism 5 software (GraphPad). Means between two groups were compared with a two-tailed, unpaired Student’s t test, except in the case of B-cell densities, which were compared by a Mann–Whitney test. Differences in cytokine/chemokine expression in the lesion of WT and muMT mice and in antibody isotype concentrations in mouse brain were compared using a two-way ANOVA. Kruskal–Wallis ANOVA and Mann’s post hoc analysis was used to compare B-cell densities in IgG⁺ and IgG⁻ subjects with control.

Results

To determine whether a B-lymphocyte response develops in the brain after stroke and contributes to delayed cognitive impairment, we searched for a mouse model of stroke that does not cause immediate cognitive impairment and thus could be used to look for the development of delayed cognitive deficits.

The most commonly used mouse stroke model, intraluminal filament MCAO, can cause immediate cognitive impairment, making it difficult to detect or study any delayed symptoms that might result from an adaptive immune response to stroke (Hattori et al., 2000; Truong et al., 2012). However, from our previous work (Doyle et al., 2012), we identified an experimental stroke paradigm: the DH stroke model in C57BL/6J mice that produces a lesion adjacent to, but not incorporating, the hippocampus and does not cause immediate cognitive impairment. This characteristic renders this model ideal for studying stroke-induced dementia.

DH stroke creates a large lesion comprising 25% of the right hemisphere, has little variability, and excellent long-term survivability (Doyle et al., 2012).

We discovered that there is substantial delayed infiltration of B-lymphocytes into infarcted tissue in the weeks after DH stroke. B-lymphocytes are virtually undetectable in the lesion 1 week after stroke (<1 cell per 40-μm-thick coronal brain section), but there is extensive infiltration at 7 weeks that is still present at 12 weeks following stroke (Fig. 1A–C). B-lymphocytes are surrounded by cells expressing the dendritic cell marker CD11c (Fig. 1C). Dendritic cells can transfer antigen to naive B cells to initiate antigen-specific antibody responses and can provide B cells with isotype-switching signals (Wykes and MacPherson, 2000). Additionally, we observed that whenever T cells and B cells were clustered together, they were compartmentalized. B cells formed the center of each cluster and were surrounded by a ring of T cells (Fig. 1D). A total of 9% of the CD19⁺ B-lymphocytes coexpressed CD138, a marker of immunoglobulin-synthesizing plasma cells (Fig. 1E).

To test whether the plasma cells in the stroke lesion were producing antibodies, we immunostained brain tissue from mice killed 7 weeks after stroke with an anti-mouse IgG secondary antibody. Immunostaining demonstrated extensive IgG in both the stroke lesion and the area adjacent to the stroke lesion, which includes the hippocampus (Fig. 1F, G). Immunostaining was most intense near the stroke lesion, suggesting that antibody might be diffusing from the lesion across the glial scar into the hippocampus and neighboring tissue. A similar finding has been reported after spinal cord injury (Ankeny et al., 2009; Ankeny and Popovich, 2010); however, it might also be diffusing from the bloodstream into this tissue if there is blood–brain barrier dysfunction in this location. In some mice, the pattern of immuno-
a multiplex immunoassay to quantify immunoglobulin in the plasma of C57BL/6 mice killed 1 and 7 weeks following stroke, and an immunostain to look for IgA-producing plasma cells within the stroke lesion 7 weeks following stroke. There was no detectable increase in IgA within the plasma in the weeks following stroke (Fig. 2B), and IgA-positive cells were present within the lesion (Fig. 2C). This suggests that, although some of the antibody present in the brain in the weeks following stroke may be from the blood, at least some of the IgA in the brain at late time points after stroke is locally produced from plasma cells within the lesion.

The initial activation of B-lymphocytes, and subsequent isotype switching, is predominantly T-cell dependent (Bishop and Hostager, 2001). Therefore, to investigate whether our discovery of a B-lymphocyte response to stroke is part of a larger adaptive immune response to stroke, we looked for the presence and relative abundance of T cells, MHCII expression, and markers of activated microglia/macrophages in the brain 7 weeks following stroke. We discovered that stroke lesions contain abundant T-lymphocytes (CD3+), MHCII-expressing cells, and activated microglia/macrophages (CD68+, Iba1+) at this time point (Fig. 3A,B; Table 1) as well as at 12 weeks following stroke (data not shown). Interestingly, in contrast to the strict localization of B cells within stroke lesions, T cells, MHCII expression, and markers of activated microglia/macrophages (CD68 and MHCII), were also detected in the thalamus, striatum, and internal capsule of each mouse 7 weeks after stroke (n = 10). These locations normally contain the axons of neurons that project from the sensorimotor cortex (McGeorge and Faull, 1989), which is the cortical region that has undergone stroke in these mice. Also, at 7 weeks after injury, Wallerian degeneration is ongoing (Vargas and Barres, 2007). This may then mean that, where slow axonal degeneration occurs, there is a chronic inflammatory response around degenerating axons for weeks after the stroke (Fig. 3C). We did not find B cells in this region (data not shown). CD3+ T-cell infiltration in the brain was also observed 4 weeks following MCAO and photothermotic stroke (Fig. 3D), demonstrating that the adaptive immune response identified with DH stroke is not stroke model specific.

Much of the antibody that is present in the mouse brain 7 weeks after DH stroke is in the hippocampus (Fig. 1F,G). LTP is one of the main neural mechanisms by which memory is stored in the hippocampus (Lynch, 2004). To determine whether antibody binding in this region impairs LTP, EPSCs were recorded from CA1 pyramidal neurons following stimulation of Schaffer collaterals projecting from CA3 pyramidal neurons. LTP was not impaired 1 week after stroke, a time point when few B cells are detectable in the lesion. Seven and 12 weeks after stroke, when there is extensive B-cell infiltration in the lesion and antibody infiltration in the hippocampus, there was significant and progressive impairment of LTP (Fig. 4A,B).

To determine whether the impaired LTP impaired cognition, we examined whether mice developed a memory deficit in the weeks after stroke. We used the Y maze, a hippocampal-dependent spatial memory task that measures the preference of rodents to explore a novel environment, and relies on their ability to remember which arms of the maze they have previously explored. Between weeks 1 and 7 following stroke, coincident with B-cell accumulation, mice developed a short-term memory deficit (Fig. 4C).

To verify that delayed cognitive impairment after stroke was generalizable to other models and not solely a function of the DH stroke model or of the C57BL/6J mouse strain, BALB/CJ mice underwent DMCAO stroke. The lesion following DMCAO in
BALB/CJ mice is equivalent in size and location to the lesion following DH stroke in C57BL/6J mice (Fig. 5A), due to strain differences in cerebral vascular anatomy (Doyle et al., 2012). Importantly, DMCAO stroke in BALB/CJ mice does not involve hypoxia. This duration of hypoxia does not directly injure the hippocampus (Doyle et al., 2012), and all sham controls in DH experiments experience the same duration of hypoxia.

Similarly to C57BL/6J mice after DH stroke, BALB/CJ mice exhibit B cells and T cells in the lesion 7 weeks following DMCAO (Fig. 5B). There was also substantial IgM, IgG, and IgA in the brain at weeks 1 and 7 after stroke (Fig. 5C). Furthermore, again similar to C57BL/6J mice following DH stroke, the amount of IgA present in the brain increased significantly between week 1 and week 7. This demonstrates that B-cell, T-cell, and antibody infiltration into the brain, as well as isotype switching after stroke, is not dependent on the hypoxia component of DH stroke. It also demonstrates that these responses are not strain specific.

BALB/CJ mice were not able to perform the Y maze task after either sham or stroke surgery due to freezing. However, they were able to perform another test of hippocampal function, the OLT, which is based on the ability of mice to remember the prior location of an object and recognize when it has been moved. They performed normally at baseline and 2 weeks following DMCAO and sham surgery (Fig. 5D). BALB/CJ mice that underwent sham surgery also performed normally 7 weeks following sham surgery. However, BALB/CJ mice that underwent DMCAO were unable to perform this test 7 weeks following stroke. This demonstrates that the hypoxia component of DH stroke is not necessary for delayed cognitive dysfunction to occur after stroke.

To test the hypothesis that B-lymphocytes contribute to the development of the delayed onset short-term memory deficit, perhaps through antibody accumulation in the hippocampus and the binding of autoreactive antibodies (Kowal et al., 2004), muMT mice that lack mature B-lymphocytes underwent stroke and memory testing. muMT mice indeed did not develop a delayed LTP deficit (Fig. 6A, B), or a cognitive deficit on either hippocampal memory task, the OLT and the Y maze (Fig. 6C, D).

To investigate the mechanism by which muMT mice are protected from delayed cognitive dysfunction following stroke, we compared lesion size, B-cell and antibody infiltration, T-cell infiltration, and cytokine expression in muMT mice and WT mice. Infarct volumes 72 h following stroke were equivalent in muMT and WT mice (Fig. 7A). Also, as expected, we did not detect B cells or IgG in the stroke lesion in muMT mice (Fig. 7B). However, T-cell infiltration and the production of proinflammatory cytokines and chemokines were equivalent in the lesion in muMT and WT mice 7 weeks after stroke (Fig. 7C, D). These data suggest that the mechanism by which B cells cause cognitive impairment after stroke is antibody mediated, rather than by an effect on T cells or cytokine production.

To investigate the translational potential of ablating B-lymphocytes after stroke, we tested whether ablating B cells using an anti-CD20 antibody could also prevent the emergence of delayed cognitive deficits. Based on our finding that it took longer than 1 week after stroke for most B-lymphocytes to infiltrate the brain, we initiated treatment five days after stroke. Mice received either a B-lymphocyte-depleting monoclonal anti-CD20 antibody (Kozakiewicz et al., 2013), or an isotype control antibody, via tail vein injection every 2 weeks following the first injection, for a total of 6 weeks. Anti-CD20 antibody treatment successfully ablated B cells in the circulation (Fig. 8A, B), prevented the appearance of delayed cognitive deficits (Fig. 8C), and prevented the recruitment of B cells and IgG to the brain (Fig. 8D–F). None of these effects was observed in mice treated with the control antibody. Anti-CD20 antibody treatment did not ablate T cells in the circulation (Fig. 8A) or alter T-cell recruitment to brain after stroke (data not shown).

Finally, to determine whether this new mouse model might be relevant to human post-stroke dementia, we evaluated
B-lymphocyte responses in human postmortem brain tissue from the Rush Religious Orders Study and Rush Memory and Aging Project (Bennett et al., 2012a, b; Boyle et al., 2013). Our criteria were the presence of infarct and no pathologic diagnosis of Alzheimer’s disease or other neuropathological disorder. Controls were matched subjects without stroke or dementia. We immunostained sections containing ischemic infarcts with CD20 to detect B cells (Fig. 9A).

We discovered 11350 B-lymphocytes/cm² in the stroke core and area adjacent to the stroke core in 19 of 21 subjects (Fig. 9B; Table 2). Nine of the subjects had 1–10 B-lymphocytes/cm² in the ischemic area, 9 exhibited 11–100, and 1 had >100 B-lymphocytes/cm². In 9 control subjects, B-lymphocyte density ranged from 0 to 3.6 lymphocytes/cm², significantly different from those with stroke (Fig. 9B). These results suggest that a B-lymphocyte response to stroke occurs in the CNS after stroke in some people.

Furthermore, IgG immunostaining revealed that antibodies are present in the brain in stroke survivors to a greater extent than in controls. Control brains uniformly contained IgG in the white matter, vasculature, and meninges, with little to no immunostaining in the neuropil. In contrast, sections from 5 of the 21 stroke subjects exhibited cellular patterns of IgG immunostaining that appeared different from subject to subject. This may be indicative of autoantibodies binding to a diverse array of CNS antigens. Figure 9C depicts 1 of 2 control subjects whose brain exhibited light immunostaining for IgG and also depicts 1 of the 5 subjects with well-defined anti-IgG immunostaining in the neuropil that was scored as “IgG +.” There was no significant difference between B-cell densities in subjects without IgG in the neuropil and controls; however, subjects with IgG immunoreactivity in the neuropil exhibited higher B-cell densities than controls (Fig. 9D).

Discussion

Our findings in mice demonstrate that B-lymphocyte-mediated inflammation in a stroke lesion can directly impact cognition. To our knowledge, this is the first time that chronic inflammatory responses in the infarct core in general, or B-lymphocyte re-
Figure 6. B-cell-deficient muMT mice do not develop either LTP or cognitive deficits in the weeks after stroke. 

**A**. Whole-cell EPSCs were recorded from CA1 pyramidal neurons in acute hippocampal slices prepared from WT and muMT mice that had undergone DH stroke or sham surgery 12 weeks earlier (n = 6–9 per group). The time course (A) and magnitude (B) of LTP demonstrated that muMT mice that had undergone DH stroke did not develop an LTP impairment 12 weeks following stroke. *p < 0.05, compared with WT sham control. There was no difference between sham groups (p = 0.85). LTP plot represents 0–40 min after LTP. Values in the bar graph were taken at 35 min after LTP. 

**B**. WT, but not muMT, mice developed a cognitive deficit on the Y maze 7 weeks after DH stroke (n = 10 per group). *p < 0.05, compared with sham.

Figure 7. Lesion size and the T-lymphocyte response to stroke are equivalent in WT and muMT mice. 

**A**. B-cell-deficient muMT mice and wild-type (WT) C57BL/6J mice had equivalent infarct volumes 72 h after DH stroke (n = 5 per group). 

**B**. muMT mice did not have B cell (B220+) or IgG immunostaining in the lesion 7 weeks after DH stroke (n = 10). Scale bar, 125 μm. 

**C**. The number of T cells in the brain was equivalent in WT and muMT mice 7 weeks after stroke. 

**D**. Levels of proinflammatory cytokines and chemokines in the lesion were similarly elevated in both WT and muMT mice compared with corresponding cortical tissue from sham mice 7 weeks after DH stroke (sham, n = 4 per group; DH stroke, n = 7 per group). There was no difference between WT and muMT mice by two-way ANOVA. The p value before correcting for multiple comparisons is shown for IL12p40 and TNFα, which were not different statistically.
sponses in particular, have been shown to cause delayed-onset cognitive impairment after stroke.

We found that by 4–7 weeks after stroke there are both B- and T-lymphocytes present in the stroke core in four different stroke models: DH, transient proximal MCAO, and photothrombotic stroke in wild-type C57BL/6J mice, and DMCAO stroke in wild-type BALB/CJ mice. We also demonstrated that mice develop delayed cognitive deficits following DH stroke in C57BL/6J mice and DMCAO in BALB/CJ mice. We used these mouse models because they do not cause an immediate cognitive deficit, and different stroke models in each strain because they each have different vulnerabilities to DMCAO.

In BALB/CJ mice, DMCAO generates a lesion that incorporates the frontal and parietal cortex and is adjacent to, but does not incorporate, the hippocampus. In C57BL/6J mice, DMCAO only generates a small lesion in the frontal cortex, and hypoxia is required to enlarge the lesion to the parietal cortex and place it in closer proximity to the hippocampus (Doyle et al., 2012). In both models, an immediate short-term memory deficit is lacking. However, mice develop a deficit within 7 weeks of a DH or DMCAO stroke. C57BL/6J mice that underwent DMCAO (without hypoxia) did not develop a short-term memory deficit (data not shown). Enlargement of the lesion in C57BL/6J mice might be important for the emergence of the delayed cognitive deficit because the larger lesion is in cortex adjacent to the hippocampus.

The delayed appearance of cognitive deficits in our mouse models mimics what is observed in human studies where stroke survivors without dementia have an at least twofold risk of developing dementia in the decade following their stroke (Desmond et al., 2002; Ivan et al., 2004). The chronic inflammation we observe in mice is also consistent with the B-lymphocytes and human IgG we observed in the brains of people who died with stroke and dementia. Consistent with our findings here, Mena et al. (2004) and Mărgăritescu et al. (2009) reported persistent immune cell infiltration, sometimes decades after stroke, in ~40% of human cerebral infarcts stained with hematoxylin and eosin.

Within the stroke lesion in mice, B-lymphocytes aggregated into clusters and were surrounded by macrophages and
T-lymphocytes, and so may represent tertiary lymphoid structures. Similar aggregates have been found in sites of chronic inflammation in other diseases, where they correlate with increased severity of disease (Ankeny et al., 2006, 2009; Carragher et al., 2008; Ankeny and Popovich, 2010; Neyt et al., 2012). In addition to IgG, we found evidence of IgA production in mice, similar to that reported in human multiple sclerosis (Bernheimer et al., 1983; Zhang et al., 2005).

Chronic inflammation is unlikely to be due to bacterial brain infection because it occurs in photothrombotic stroke, which does not require the skull to be opened. There was also no evidence of bacteria on hematoxylin and eosin stains of brain sections from C57BL/6J mice killed on days 1, 3, and 7 or 1 and 3 months after DH stroke (data not shown).

B-lymphocyte aggregates have been found in mice in the injured spinal cord where they produce antibodies and impair recovery (Ankeny and Popovich, 2010). Here, we showed that a substantial amount of antibody is present in areas of the brain adjacent to B-cell clusters that form in the stroke core. We speculate that plasma cells in the stroke core might be producing autoreactive antibodies or antibodies that activate Fc receptors and complement, and that those antibodies diffuse into the surrounding tissue and cause neurological dysfunction. In support of this hypothesis, we observed a deficit in hippocampal LTP in a time frame similar to that of antibody accumulation. The development of a deficit in LTP could explain why mice acquired a short-term memory deficit in the weeks after stroke.

Ankeny et al. (2006, 2009) have shown that B-lymphocyte-deficient mice have improved locomotor function and reduced spinal pathology after spinal cord injury compared with wild-type mice. Therefore, we tested whether B-lymphocyte-deficient muMT mice were protected from delayed cognitive deficits after stroke. We found that the genetic ablation of mature B-lymphocytes prevented the emergence of delayed cognitive deficits.

To investigate the translational potential of ablating B-lymphocytes after stroke, we tested whether ablating B cells using intravenous administration of an anti-CD20 antibody could also prevent the emergence of delayed cognitive deficits. We began treatment 5 d after stroke, and antibody treatment successfully ablated B cells in the circulation, prevented their recruitment to the brain, and prevented the appearance of delayed cognitive deficits. A chimeric version of the monoclonal anti-CD20 antibody we used here, rituximab, is FDA-approved as a B-cell-depleting drug for rheumatoid arthritis, CD20+ non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis (Grillo-López et al., 1999, 2002; Montserrat, 2003; Perosa et al., 2010; Scher, 2012). Intrathecal administration of rituximab, as used in CNS lymphoma and multiple sclerosis (Rubenstein et al., 2003; Studer et al., 2014), might also be effective. It was also recently shown that 124I-rituximab could be used to image CD20-positive B-lymphocytes at sites of inflammation in patients with rheumatoid arthritis using PET imaging (Tran et al., 2011). Thus, trace amounts of rituximab could be used to identify the presence of B-lymphocytes in the brains of stroke patients and potentially identify those that might benefit from rituximab treatment after stroke.

Ren et al. (2011) reported that regulatory B cells limit CNS inflammation and are beneficial for outcomes in the first few days after stroke, although others reported that B cells are of minor relevance during the acute phase of stroke injury (Kleinschnitz et al., 2010). Regardless of these findings in the acute phase of
stroke, the data we present here demonstrate that B cells cause later neurologic impairment weeks after stroke. This may be similar to the reciprocal role of B cells in experimental EAE. In EAE, IL10-expressing regulatory B cells are beneficial early in disease, but other B cells are detrimental later (Matsushita et al., 2008). We postulate that, early in stroke, IL10-producing regulatory B cells may be beneficial, whereas later during recovery from stroke, autoantibody-producing plasma cells become detrimental.

We also postulate that the mechanism by which B-lymphocytes contribute to cognitive dysfunction after stroke is via the production of brain-reactive antibodies. Brain-reactive antibodies are linked to pathogenesis in many other neurological disorders, such as spinal cord injury, systemic lupus erythematosus, and neuromyelitis optica, and can recognize and interfere with many molecules important for key brain functions, such as neurotransmission, blood–brain barrier function, and protein translation (for review, see Diamond et al., 2009). In addition, autoantibodies can ligate Fc receptors, initiate cytokine signaling pathways, and activate complement. It is not yet clearly established by which of these mechanisms brain-reactive antibodies contribute to symptoms of disease in the CNS, but it is likely that a different combination of mechanisms is important in different diseases and individuals.

The mechanism by which B-lymphocytes contribute to cognitive dysfunction is likely to involve T-lymphocytes. We found abundant T-lymphocytes and MHCII expression in the lesion and in an area of Wallerian degeneration 7 weeks following stroke, and the presence of these cells, in conjunction with pro-inflammatory cytokines is suggestive that stroke elicits a prolonged T-lymphocyte response within the brain. Additionally, we found evidence of isotype switching, which is typically T-cell-dependent (Bishop and Hostager, 2001; Cerutti, 2008), with increased IgA present in the brain 7 weeks following stroke in both mouse models. However, muMT mice did not develop delayed cognitive deficits after stroke yet had equivalent T-cell infiltration and cytokine concentrations in the brain as wild-type C57BL/6J mice. These T-cell responses alone were thus not sufficient to cause electrophysiologic or cognitive deficits in the absence of B-lymphocytes.

There are limitations to using rodents to model cognitive dysfunction in humans. For instance, stroke patients often have multiple comorbidities, such as age, periventricular white matter disease, other types of vascular dementia, and Alzheimer’s disease (Barba et al., 2000; Ivan et al., 2004; Leys et al., 2005; Troncoso et al., 2008; Savva and Stephan, 2010; Gorelick et al., 2011; Iadecola, 2013). Indeed, in human populations, classic neuropathological findings of disease, including strokes and other vascular pathology, explain only 41% of the risk of overall cognitive decline (Boyle et al., 2013). However, we present evidence here from autopsy tissue that implicates B-lymphocyte infiltration as a novel factor that potentially confers an increased risk of cognitive decline to humans with stroke and may contribute to a more comprehensive understanding of cognitive impairment. It will now be important to define both the duration and characteristics of adaptive immune responses in people who have suffered a
stroke and determine whether they correlate with the development of poststroke dementia in some patients.

References

Doyle et al. (2015) B-Lymphocytes Impair Cognition Late after Stroke


Tran L, Huitrema AD, van Rijwijs MH, Dinh HT, Baars JW, Beijnen JH, Vogel WV (2011) CD20 antigen imaging with (1)2(4)-R-rituximab